AbbVie Inc. (ABBV)
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Novo Nordisk is a great business, but its dividend profile isn't nearly as impressive. That contrasts with AbbVie's dividend record, which has proven excellent over time.
AbbVie's Parkinson's Disease drug meets main goal in late-stage trial
AbbVie said on Thursday its drug met the main goal in a late-stage trial in patients with early Parkinson's disease.
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock . BMY stock trades at a much lower multiple of 2.2x revenues, versus 6.2x for ABBV.
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
The latest trading day saw AbbVie (ABBV) settling at $191.26, representing a -1.16% change from its previous close.
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
Raise Cash And Sell Trash
As a dividend growth investor focused on income, I recommend raising cash and selling lower-quality stocks due to potential recession risks. Historical data shows that rate cuts often precede recessions, making it prudent to increase cash positions and reduce exposure to vulnerable stocks. Despite some reasonable buying opportunities, I prefer holding cash in ETFs like SGOV for liquidity and safety during uncertain economic times.
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former lead drug Humira.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued.
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Analyzing the board of directors is a quick way to assess people power. Scientific advisory boards are easier to analyze than they might seem.
3 Stocks to Buy and Hold Forever
AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
AbbVie is a Dividend King that's proven it can successfully navigate patent cliffs. Brookfield Infrastructure offers attractive distributions and has a solid long-term growth strategy.
